Medical Component Specialists Expands Quick Ship Program

August 15, 2024 9:00 AM

BELLINGHAM, MA / ACCESSWIRE / August 15, 2024 / For medical device manufacturers, having the right suppliers ensures necessary components can be obtained whenever needed. For this reason, Medical Component Specialists' Quick Ship Program provides next-day shipping for over 400 catheter-forming mandrels and raw materials.Quick Ship Product Announcement Recently, the Quick Ship Program expanded to include PTFE GLASS filled and Nitinol...

Read more

Sagesse Bio Accelerates Development of SGY-101 into clinical development for Targeted Fat Reduction in Aesthetic Medicine and Medical Dermatology

August 15, 2024 9:00 AM

Sagesse Bio, an early-stage pharmaceutical company in aesthetic medicine and medical dermatology with a focus on body contouring and focal fat reduction announces its plans to rapidly develop its lead asset SGY-101 with backing from Gore Range Capital LLC (Gore Range Capital), a leading healthcare investment firm and Sirnaomics LTD (Sirnaomics), a leader in RNAi technology. Gore Range Capital will contribute its expertise in the skin health...

Read more

Scientific Industries Reports Second Quarter 2024 Results

August 15, 2024 9:00 AM

Scientific Industries, Inc. (OTCQB:SCND), a life sciences tool provider, and a developer of digitally simplified bioprocessing products, yesterday reported financial results for the three and six month periods ended June 30, 2024.Business Highlights:The Company's newly launched Bioprocessing DOTS MPS gains market traction.The Company introduced the VIVID Workstation at major trade shows.John Nicols, Chairman of SBI and Board member, was a guest...

Read more

Communication Service for the Deaf, Inc. Receives $250,000 Engagement Award from PCORI

August 15, 2024 8:30 AM

AUSTIN, TX / ACCESSWIRE / August 15, 2024 / Communication Service for the Deaf, Inc. (CSD) has been awarded $250,000 through the Eugene Washington PCORI Engagement Award Program, an initiative of the Patient-Centered Outcomes Research Institute (PCORI). The funding will support a two-year project titled "Building Capacity for Deaf American Sign Language Users in Virtual Healthcare PCOR/CER," running from November 1, 2024 through October 31,...

Read more

CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results

August 15, 2024 8:00 AM

HOUSTON, TX / ACCESSWIRE / August 15, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the second quarter 2024 ended June 30, 2024."It has been an important year for CNS Pharmaceuticals with completion of enrollment in our...

Read more

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

August 15, 2024 7:30 AM

Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac's mRNA platformInitiated strategic workforce reduction of ~30% by end of 2024, optimizing business to focus on high-value opportunities in oncology, infectious diseases and other areasInvoiced €10 million milestone payment after Phase 2 transition of pre-pandemic avian influenza (H5N1) program; candidate fully...

Read more

CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

August 15, 2024 7:20 AM

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the start of the dose-confirmation Part B of its ongoing Phase 1 study in patients with resected glioblastoma. CVGBM is CureVac's first investigational cancer vaccine based on its proprietary...

Read more

CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board

August 15, 2024 7:15 AM

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today named clinical oncologist Mehdi Shahidi, M.D., as an independent director to the company's Supervisory Board. Dr. Shahidi replaces Ralf Clemens, who served on the Supervisory Board from March 2016 through...

Read more

Beta Bionics Celebrates Milestone: 10,000th iLet Patient

August 15, 2024 7:00 AM

CONCORD, MA / ACCESSWIRE / August 15, 2024 / Beta Bionics, a commercial-stage medical technology company, proudly announces the 10,000th patient start on the iLet Bionic Pancreas. This significant milestone marks a major step forward in the company's mission to alleviate the daily burden of diabetes management for patients and healthcare providers alike.iLet With Dexcom G7 The iLet Bionic Pancreas is the first FDA-cleared autonomous closed-loop...

Read more

BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations

August 15, 2024 3:05 AM

BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a non-binding letter of intent (the "LOI") with German-based international contract research, development, and manufacturing company Gen-Plus GmbH & Co KG ("Gen-Plus"), a part of Conscio Group.Further to the Master Service Agreement and Cladribine Statement of Work signed by BioNxt and Gen-Plus announced on July 9, 2024, and...

Read more

Half-Year Report 2024: Orviglance Completes Clinical Development with Successful Phase 3 Study

August 15, 2024 1:50 AM

MALMÖ, SWEDEN / ACCESSWIRE / August 15, 2024 / Ascelia Pharma (STO:ACE) Ascelia Pharma AB (publ) (ticker: ACE) today published its Half-Year Report for 2024 (January - June), which is now available on the company's website: https://www.ascelia.com/ir-media/financial-reports/KEY EVENTS IN Q2 2024SPARKLE image reading completed with expected headline results first half of May 2024Ascelia Pharma draws down SEK 15 million second tranche under...

Read more

NHI Announces Pricing of Upsized Public Offering of Common Stock

August 14, 2024 9:00 PM

National Health Investors, Inc. (NYSE:NHI) (the "Company") announced today the pricing of an underwritten public offering of 2,400,000 shares of its common stock at a public offering price of $71.25 per share, all of which will be offered on a forward basis through the forward purchasers (as defined below) or their respective affiliates in connection with the forward sale agreements described below. The underwriters were also granted a 30-day...

Read more

GLG Life Tech Corporation Reports 2024 Second Quarter Financial Results

August 14, 2024 7:10 PM

GLG Life Tech Corporation (TSX:GLG) ("GLG" or the "Company"), a global leader in the agricultural and commercial development of high-quality zero-calorie natural sweeteners, announces financial results for the three and six months ended June 30, 2024. The complete set of financial statements and management discussion and analysis are available on SEDAR and on the Company's website at www.glglifetech.com.FINANCIAL SUMMARYThe Company reported...

Read more

Medicure Announces Closing of Asset Purchase Agreement with Canam Bioresearch for Acquisition of Intellectual Property

August 14, 2024 5:30 PM

Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, is pleased to announce that, further to its news release on June 24, 2024, it has acquired certain intellectual property assets of CanAm Bioresearch Inc. ("CanAm") related to the discovery of new chemical entities...

Read more

Medicure Reports Financial Results for Quarter Ended June 30, 2024

August 14, 2024 5:00 PM

Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended June 30, 2024.Quarter Ended June 30, 2024 Highlights:Recorded total net revenue of $5.2 million during the quarter ended June 30, 2024 compared to $6.0...

Read more

Acreage Reports Second Quarter 2024 Financial Results

August 14, 2024 4:30 PM

Commenced Non-Medical Sales in Ohio Market, Expected to Double Revenue in the State by 2025 from ~$50 million in 2023Focused on re-accelerating growth in core states including New Jersey, Illinois, and Connecticut in the second half of 2024Advancing acquisition by Canopy USA; expected to close in the first half of calendar 2025NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Acreage Holdings, Inc. ("Acreage" or the "Company") (CSE:ACRG.A.U,...

Read more

Interactive Strength Inc. (Nasdaq: TRNR) Reports Second Quarter 2024 Results

August 14, 2024 4:25 PM

Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or the "Company"), maker of innovative specialty fitness equipment under the CLMBR and FORME brands, today announced its financial results for the second quarter of 2024.The Company incurred a net loss of $10.6 million for the second quarter of 2024, or a loss of $17.48 per diluted share, as compared with a net loss of $13.6 million, or a loss of $40.78 per diluted share for the same period in...

Read more

Monogram Technologies Reports Second Quarter 2024 Financial Results

August 14, 2024 4:05 PM

Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, has reported its financial and operational results for the second quarter ended June 30, 2024.Second Quarter 2024 and Subsequent Operational HighlightsSubmitted a 510(k) premarket filing to the U.S. Food and Drug Administration (FDA) for the Company's mBôs TKA System...

Read more

Zomedica Announces Second Quarter 2024 Financial Results: Revenue of $6.1 Million; 71% Gross Margin, and $83.0 Million in Liquidity to Support Growth

August 14, 2024 4:05 PM

ANN ARBOR, MI / ACCESSWIRE / August 14, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the second quarter ended June 30, 2024."We are pleased with the progress in the quarter, which represents the highest second quarter for the Company to date. We saw...

Read more

NHI Announces Public Offering Of Common Stock

August 14, 2024 4:02 PM

National Health Investors, Inc. (NYSE:NHI) (the "Company") announced today that it has commenced an underwritten public offering of 2,000,000 shares of its common stock, all of which will be offered on a forward basis through the forward purchasers (as defined below) or their respective affiliates in connection with the forward sale agreements described below. The underwriters of the offering also expect to be granted a 30-day option to purchase...

Read more